- Acquired by Mori Arkin, Jul 2014
- Raised $7M funding round, Jun 2006
- Raised $19M funding round
About
Sol-Gel Technologies is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its current product candidate pipeline consists of late-stage branded product candidates that leverage its proprietary silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
Sol-Gel was successful in developing pioneer topical drugs, Twyneo and Epsolay, for the treatment of acne and inflammatory lesions of rosacea. Both products are marketed in the US by Galderma since 2022.
The company is developing topical patidegib that is expected to be approved for the treatment of Gorlin syndrome and topical erlotinib for the treatment of pachyonychia congenita and other rare skin indications.
Funding history · 3 rounds · $146.0M total
Q&A
- What is Sol-Gel Technologies' primary focus?
- Sol-Gel Technologies is a clinical-stage dermatology company that identifies, develops, and commercializes branded and generic topical drug products for skin diseases.
- What proprietary technology does Sol-Gel Technologies leverage?
- The company leverages a proprietary silica-based microencapsulation technology platform for its product candidates.
- Which topical drugs developed by Sol-Gel Technologies are currently marketed in the US?
- Twyneo and Epsolay, developed for the treatment of acne and inflammatory lesions of rosacea, respectively, have been marketed in the US by Galderma since 2022.
- What are some of Sol-Gel Technologies' pipeline products?
- The company is developing topical patidegib for Gorlin syndrome and topical erlotinib for pachyonychia congenita and other rare skin indications.
- When was Sol-Gel Technologies founded?
- Sol-Gel Technologies was founded in October 1997.
- How many employees does Sol-Gel Technologies have?
- Sol-Gel Technologies has 11-50 employees.
- Who acquired Sol-Gel Technologies?
- Sol-Gel Technologies was acquired by Mori Arkin in July 2014.
- What is Sol-Gel Technologies' primary sector?
- The company's primary sector is Health Tech & Life Sciences.
- Who is a co-founder of Sol-Gel Technologies?
- Dr. Alon Seri-Levy is a Co-Founder & CEO of Sol-Gel Technologies.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | sol-gel.com/ |
|---|---|
| linkedin.com/company/1117260 | |
| Wikidata | wikidata.org/wiki/Q106411767 |
Identifiers & details
| Founded | 1997-10 |
|---|---|
| Employees (exact) | 48 |
| Market cap | $117.4M |
| Status reason | Acquired by Mori Arkin on Jul, 2014 |
| Wikidata QID | Q106411767 |
Acquisitions & public offerings
Acquired by Mori Arkin 2014-07
Radar intelligence
Patents
| EPO | 97 |
|---|
Web history (Wayback)
| Domain | sol-gel.com |
|---|
Wikidata
| QID | Q106411767 |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|